The American pharmaceutical group Pfizer closed the first quarter of 2021 with revenues of $ 14.582 billion, an increase of 45% compared to the same period of 2020. From the vaccine for Covid-19 alone, revenues of 3.5 billion were received. dollars.
The company announced this in a statement adding that in the first 3 months the group achieved earnings per share of $ 0.93, up 47% on a trend basis. Based on the results achieved Pfizer has also announced that it has revised upwards its annual sales forecasts for the Covid-19 vaccine that it has developed together with the German BioNTech.
Loading…
Vaccine revenues soar
The US pharmaceutical company now expects sales of $ 26 billion related to the vaccine in 2021, up from its previous forecast of about $ 15 billion. The target assumes that 1.6 billion doses of the vaccine will be administered during the year. In reality, Pfizer and BioNTech aim to produce 2.5 billion vials in 2021, in which case revenues would rise well beyond the estimated $ 26 billion so far.
Estimates for 2021 improve
As a result, Pfizer improves guidance for 2021 and now expects revenues to range between $ 70.5 and $ 72.5 billion. Previous guidance saw revenues of between $ 59.4 and $ 61.4 billion. Over a third of the revenues will therefore come from the Covid vaccine.
Next step: teen vaccination
“I could not be more proud of how Pfizer started 2021 – said the managing director Albert Bourla – Based on what we have seen so far, we foresee a lasting demand for our vaccine“. The American health authorities in the next few days could give authorization for the administration of the Pfizer vaccine even in the age group from 12 to 15 years. EMA, the European Medicines Agency, is also examining this possibility. Pfizer plans to present vaccine efficacy data for children aged 2 to 11 in September.